Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside

Cancer Treatment Reviews

Volumn 40, Issue 9, 2014, Pages 1039-1047

  Oettle, Helmut ^a  

^a Berlin and Onkologische Schwerpunktpraxis   (Germany)

Author keywords

Advanced pancreatic cancer; Clinical trial; Palliative chemotherapy; Tumor microenvironment; Tumor stroma

Indexed keywords

CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYALURONIC ACID; IRINOTECAN; JANUS KINASE; OSTEONECTIN; OXALIPLATIN; PACLITAXEL; RUXOLITINIB; SONIC HEDGEHOG PROTEIN; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADVANCED CANCER; CANCER ASSOCIATED STROMAL FIBROBLAST; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; MAST CELL; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATIC STELLATE CELL; REVIEW; STROMA; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; STROMA CELL;

ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUOROURACIL; HUMANS; HYALURONIC ACID; MAST CELLS; PACLITAXEL; PANCREATIC NEOPLASMS; STROMAL CELLS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84926663221     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.07.003     Document Type: Review

References (63)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
2. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7:163-172.
3. Lombardi L., Troiano T., Silvestris N., Nanni L., Latiano T.P., Di Maggio G., et al. Combined modality treatments in pancreatic cancer. Expert Opin Ther Targets 2012, 16(Suppl. 2):S71-S81.
4. O'Reilly E. Refinement of adjuvant therapy for pancreatic cancer. JAMA 2010, 304(10):1124-1125.
5. Malik N.K., May K.S., Chandrasekhar R., Ma W.W., Flaherty L., Iyer R., et al. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol 2012, 3(4):326-334.
6. Larsson S.C., Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012, 106(3):603-607.
7. Licv D., Morris J.S., Liu J., Hassan, Sue Day R., Bondy M.L. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009, 301(24):2553-2562.
8. Liao K.F., Lai S.W., Li C.I., Chen W.C. Diabetes mellitus correlated with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012, 27(4):709-713.
9. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
10. Bujanda L., Herreros-Villanueva M., Hijona E., Cosme A. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012, 18(14):1565-1572.
11. Oettle, Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., et al. Adjuvant therapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013, 310(14):1473-1481.
12. Gillen S., Schuster T., Meyer Zum Buschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systemic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7(4):e1000267.
13. Hammel P, Huguet F, Van Laethem J-L, Goldstein D, Glimelius B, Artru P et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study.2013 ASCO Annual Meeting; 2013 May 31-Jun 4; Chicago, Illinois, USA; J Clin Oncol 31(Suppl.; abstr LBA4003).
14. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
15. Heinemann V., Boeck S., Hinke A., Labianca R., Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination therapy applied in patients with advanced pancreatic cancer. BMC Cancer 2008, 8(82).
16. Neoptolemos J.P., Greenhalf W., Ghaneh P., Palmer D.H., Cox T.F., Garner E. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. J Clin Oncol 2013, 31. [abstr 4006].
17. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1):187-195.
18. http://www.clinicaltrials.gov/ct2/NCT01726582?term=NCT017265829%26rank=1.
19. Hofmann I., Weiss A., Elain G., Schwaederle M., Sterker D., Romanet V., et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS ONE 2012, 7(8):e44146.
20. Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013, 497(7451):638-642.
21. Jones S., Zhang X., Wiilams Parsons D., Cheng-Ho Lin J., Leary R.J., et al. Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
22. Kalluri R., Weiberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420-1428.
23. Castellanos J.A., Merchant N.B., Nagathihalli N.S. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther 2013, 6:1261-1267.
24. Katsuno Y., Lamouille S., Derynck R. TGF-β signalling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 2013, 25(1):76-84.
25. Oettle H, Hilbig A, Seufferlein T, Luger T, Schmid R, von Wichert G et al. Trabedersen (AP 2009) for the treatment of patients with advanced tumors: a phase I/II study. 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida, USA. abstr. 5506. Available from . http://www.aacr.org.
26. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009, 69(14):5820-5828.
27. Buck E., Eyzaguirre A., Barr S., Thompson S., Sennello R., Young D., et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 2007, 6:532-541.
28. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction of pancreatic cancer, from inception to invasion. Cancer Res 2007, 67(19):9518-9527.
29. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616.
30. Heinemann V., Reni M., Ychou M., Richel D.J., Macarulla T., Ducreux M. Tumour-stroma interactions in pancreatic ductal carcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev 2013, [pii: S0305-7372(13)00089-3].
31. Luo G., Long J., Zhang B., Liu C., Xu J., Ni Q., et al. Stroma and pancreatic ductal adenocarcinoma: an interaction loop. Biochim Biophys Acta 2012, 1826(1):170-178.
32. Mahadevan D., Von Hoff D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007, 6(4):1186-1197.
33. Kikuta K., Masamune A., Watanabe T., Ariga H., Itoh H., Hamada S., et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 2010, 403:380-384.
34. Phillips P. Pancreatic stellate cells and fibrosis. Pancreatic cancer and tumor microenvironment 2012, Transworld Research Network, Trivandrum (India), [Available from http://www.ncbi.nih.gov/books/NBK98937]. P.J. Grippo, H.G. Munshi (Eds.).
35. Hwang R.F., Yokoi K., Bucana C.D., Tsan R., Killion J.J., Evans D.B., et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003, 9(17):6534-6544.
36. Moss R.A., Moore D., Mulcahy M.F., Nahum K., Saraiya B., Eddy S., et al. A multi-institutional Phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointest Cancer Res 2012, 5(3):77-83.
37. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic target of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21(3):418-429.
38. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. 49th Annual Meeting of the American Society of Clinical Oncology. 2013 May 31-Jun 4; Chicago, Illinois, USA. abstr. 4010. Available from . http://abstract.asco.org/AbstView%5f132%5f113132.html.
39. Walter K., Omura N., Hong S.M., Griffith M., Vincent A., Borges M., et al. Overexpression of smoothened activates the sonic hedgehog signalling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 2010, 16(6):1781-1789.
40. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
41. Catenacci DVT, Bahary N, Nattam SR, de Wilton Marsh R, Wallace JA, Rajdev L et al. Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): a University of Chicago phase II consortium study. 49th Annual Meeting of the American Society of Clinical Oncology. 2013 May 31-Jun 4; Chicago, Illinois, USA. abstr. 4012. Available from . http://abstract.asco.org/AbstView%5f132%5f117069.html.
42. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer; 27 Jan 2012. Available from . http://www.infi.com.
43. Arnold S.A., Brekken R.A. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 2009, 3:255-273.
44. Infante J.R., Matsubayashi H., Sato N., Tonascia J., Klein A.P., Riall T.A., et al. Peritumoural fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007, 25(3):319-325.
45. Desai N., Trieu V., Damascelli B., Soon-Shiong P. SPARC expression correlated with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009, 2(2):59-64.
46. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29(34):4548-4554.
47. Goldstein D., El-Maraghi R.H., Hammel P., Heinemann V., Kunzmann V., Sastre J., et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. J Clin Oncol 2014, 32. [Suppl. 3; abstract 178].
48. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369(18):1691-1703.
49. Desai N. Nab technology: a drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Delivery, Report 2007/2008. 16th ed., p. 37-41.
50. Gardner E.R., Dahut W.L., Scripture C.D., Jones J., Aragon-Ching J.B., Desai N., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008, 14(13):4200-4205.
51. Cucinotto I., Fiorillo L., Gualtieri S., Arbitrio M., Ciliberto D., Staropoli N., et al. Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime time?. J Drug Deliv 2013, 2013:1-10.
52. Ma Y., Hwang R.F., Logsdon C.D., Ullrich S.E. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res 2013, 73(13):3927-3937.
53. Deplanque G., Demarchi M., Hebbar M., Flynn P.J., Melichar B., Atkins J., et al. Masitinib in nonresectable pancreatic cancer: results of a phase III randomized placebo-controlled trial. J Clin Oncol 2013, 31. [Suppl. 4; abstr 158].
54. Quintás-Cardama A., Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013, 19(8):1933-1940.
55. Hurwitz H., Uppal N., Wagner S.A., Bendell J.C., Beck T., Wade S., et al. A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 2014, 32:5s. [Suppl.; abstr 4000].
56. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
57. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364(19):1817-1825.
58. Ho A.H. FOLFIRINOX: a small step or a great leap forward. J Clin Oncol 2011, 29(28):3727-3729.
59. Artinyan A., Soriano P.A., Prendergast C. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford) 2008, 10(5):371-376.
60. Mahaseth H, Kauh JS, Brutcher E, Hawk NN, Kim S, Chen Z et al. Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: a retrospective experience. 2012 ASCO Annual Meeting; 2012; Jun 1-5; Chicago, Illinois, USA; J Clin Oncol; 30: abstr e14614.
61. National Comprehensive Cancer Network. Available from . http://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=36.
62. Leach B. Priority Review Granted for nab-paclitaxel in pancreatic cancer. Available from . http://www.onclive.com/web-exclusives/Priority-Review-Granted-for-Nab-Paclitaxel-in-Metastatic-Pancreatic-Cancer.
63. Mulcahy N. FDA approves nab-paclitaxel for pancreatic cancer: Available from . http://www.medscape.com/viewarticle/810564.